Abstract: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving.

Abstract: The claimed subject matter relates to a device for dosing and aerosolization of aerosolizable material. The device comprises: a body with an aerosolization channel with a distal attachment portion connectable to a source of carrier gas which provides pressure pulses to the aerosolization channel; a proximal attachment portion for outputting aerosolized material and a reservoir for receiving aerosolizable material. The reservoir comprises walls and is connected in a gas-tight manner to the body and in fluid connection with the aerosolization channel. At least part of the walls of the device are self-exciting membranes that can be put into oscillation by the pressure pulses.

Abstract: The claimed subject matter is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container and closure are made of material which essentially does not release zinc ions.

Abstract: The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Abstract: Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.

Abstract: A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.

Abstract: The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising i) providing a particulate composition comprising a) calcium carbonate, b) a binding sugar alcohol selected from sorbitol or isomalt, or combinations thereof, c) a non-binding sugar alcohol selected from mannitol, maltitol or xylitol, or combinations thereof, and ii) compressing said composition using a tabletting machine equipped with at least one pair of punches and dies, wherein the pair of punches and die before filling the die with said particulate composition is sprayed with a composition comprising a lubricant selected from magnesium stearate, calcium stearate or stearic acid or combinations thereof.

Abstract: The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.

Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Abstract: Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.

Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.

Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.

Abstract: The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Abstract: A filtering device comprises a filtering means (8); a first plate-like element (4) disposed on the filtering means (8) and having at least one bore (4a); a second plate-like element (5) disposed below the filtering means (8) and having at least one bore (5a); and a plate-like adapter element (1, 2) disposed on the first plate-like element (4) and having at least one bore (1a, 2a). At least one adapter means (1b, 2b, 3) is disposed on the plate-like adapter element (1, 2) on a side opposite to the first plate-like element (4) and is open to the bore (1a, 2a) of the plate-like adapter element (1, 2). The at least one adapter means (1b, 2b, 3) is adapted for connection with a container containing a fluid to be filtered.

Abstract: The subject matter of this application relates to the combination of ciclesonide with an antihistamine.

Abstract: The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.